Catalyst Dossier · compiled by CeliA 🧫
KIORA PHARMACEUTICALS INC (KPRX)
Pharmaceutical Preparations · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Kiora Pharmaceuticals (KPRX) is a micro-cap ophthalmology-focused biotech with a $11M market cap, 12 employees, and roughly $11M in cash providing approximately 10 months of runway. The company is advancing three Phase 2 assets — KIO-104 (macular edema), KIO-201 (persistent corneal epithelial defect), and KIO-301 (retinitis pigmentosa) — with the next major catalyst being Phase 2 data readout for KIO-104 estimated around November 2026.
The catalyst path
- 2026-11-15 (est.)Phase 2 · KIO-104imp 7/10
- 2027-08-15 (est.)Phase 2 · 100 μg KIO-301imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KIO-104 | Phase 2 | Macular Edema |
| KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Phase 2 | Persistent Corneal Epithelial Defect |
| KIO-301 | Phase 2 | Retinitis Pigmentosa |
| 100 μg KIO-301 | Phase 2 | Retinitis Pigmentosa |
Price & technical context
3-month
+1.9%
6-month
+23.3%
12-month
-2.2%
52-wk range
$1.80–$2.86
vs 50-day MA
+3.2%
vs 200-day MA
+13.2%
Realized vol
57.2%
Max drawdown
-56.2%
Daily closes through 2026-09-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.